SwePub
Sök i SwePub databas

  Utökad sökning

Träfflista för sökning "hsv:(MEDICIN OCH HÄLSOVETENSKAP) hsv:(Klinisk medicin) hsv:(Cancer och onkologi) srt2:(2000-2004)"

Sökning: hsv:(MEDICIN OCH HÄLSOVETENSKAP) hsv:(Klinisk medicin) hsv:(Cancer och onkologi) > (2000-2004)

Sortera/gruppera träfflistan
   
NumreringReferensOmslagsbildHitta
71.
  • Suo, Zhenhe, et al. (författare)
  • The expression of EGFR family ligands in breast carcinomas
  • 2002
  • Ingår i: International Journal of Surgical Pathology. - Thousand Oaks, USA : Sage Publications. - 1066-8969. ; 10:2, s. 91-99
  • Tidskriftsartikel (refereegranskat)abstract
    • Expression of EGF, HB-EGF, TGF-alpha, HRG-alpha, HRG-beta1, and HRG-beta3 in 100 frozen breast carcinoma materials was immunohistochemically studied. Among these tumors, 67% were positive for EGF, 53% for HB-EGF, 57% for TGF-alpha, 60% for HRG-alpha, 53% for HRG-beta1, and 63% for HRG-beta3 in the neoplastic epithelial cells. No significant associations between expression of the growth factors and clinicopathological features like tumor size, histologic grade, node status, ploidy, ER status, and c-erbB-4 expression were observed, with the exceptions that significant relations were present between EGF expression and tumor size (p = 0.01) and between HRG-beta3 expression and node status (p = 0.02). The expressions of these growth factors showed no association with cancer-specific survival by the Kaplan Meier analysis.
  •  
72.
  • Uggla, Bertil, 1962-, et al. (författare)
  • Expression of topoisomerase IIalpha in the G0/G1 cell cycle phase of fresh leukemic cells
  • 2001
  • Ingår i: Leukemia research : a Forum for Studies on Leukemia and Normal Hemopoiesis. - Oxford, United Kingdom : Elsevier. - 0145-2126. ; 25:11, s. 961-966
  • Tidskriftsartikel (refereegranskat)abstract
    • Topoisomerase IIalpha (topoII alpha) is the target enzyme for several antineoplastic drugs. Correlation between low expression of topo IIalpha and drug resistance has been shown in vitro, but there is limited evidence of a correlation to initial response to treatment or to overall prognosis. Normal cells express topo IIalpha in S/G2/M phase of the cell cycle but not in G0/G1 phase. However, some data suggest that topo IIalpha could be expressed in G0/G1 phase in malignant cells. We have investigated the expression of topo IIalpha in leukemic cells from 25 patients with acute leukemia by flow cytometry, separating cells of different cell cycle phases. We demonstrated that 9/25 samples showed >50% positive cells in G0/G1, and another five samples showed >20%. This finding could possibly provide an explanation to previous difficulties in correlating topo IIalpha expression with clinical outcome. Six of eight patients, where >20% of the cells in G0/G1 were positive for topo IIalpha, entered CR, compared to one of five patients with <20% topo IIalpha positive cells in G0/G1. We suggest that topo IIalpha expression in G0/G1 in leukemic cells may be of predictive value for clinical response to cytostatic drugs.
  •  
73.
  • Villman, Kenneth, et al. (författare)
  • Topoisomerase II-α expression in different cell cycle phases in fresh human breast carcinomas
  • 2002
  • Ingår i: Modern Pathology. - Baltimore : Lippincott Williams & Wilkins. - 0893-3952. ; 15:5, s. 486-491
  • Tidskriftsartikel (refereegranskat)abstract
    • Topoisomerase II-alfa (topo IIalfa) is the key target enzyme for the topoisomerase inhibitor class of anti-cancer drugs. In normal cells, topo IIalfa is expressed predominantly in the S/G2/M phase of the cell cycle. In malignant cells, in vitro studies have indicated that the expression of topo IIalfa is both higher and less dependent on proliferation state in the cell. We studied fresh specimens from 50 cases of primary breast cancer. The expression of topo IIalfa in different cell cycle phases was analyzed with two-parameter flow cytometry using the monoclonal antibody SWT3D1 and propidium iodide staining. The expression of topo IIalfa was significantly higher in the S/G2/M phase of the cell cycle than in the G0/G1 phase in both DNA diploid and DNA nondiploid tumors. In 18 of 21 diploid tumors, and in 25 of 29 nondiploid tumors, >50% of the topo IIalfa–positive cells were in the G0/G1 phase. This significant expression of topo IIalfa in the G0/G1 phase of the cell cycle may have clinically important implications for treatment efficacy of topoisomerase II inhibitors.
74.
  • Wu, Qinghua, et al. (författare)
  • Expression of Ephb2 and Ephb4 in breast carcinoma
  • 2004
  • Ingår i: Pathology and Oncology Research. - Budapest, Hungary : Arányi Lajos Foundation. - 1219-4956. ; 10:1, s. 26-33
  • Tidskriftsartikel (refereegranskat)abstract
    • Eph receptor tyrosine kinases and their cell-surface-bound ligands, the ephrins, play key roles in diverse biological processes. Eph receptors comprise the largest family of receptor tyrosine kinases consisting of eight EphA receptors (with five corresponding ephrinA ligands) and six EphB receptors (with three corresponding transmembrane ephrinB ligands). Originally identified as neuronal pathfinding molecules, EphB receptors and ephrinB ligands are later proved to be crucial regulators of vasculogenesis and embryogenesis. More studies indicate that Eph receptors are involved in angiogenesis and tumorigenesis. This study aimed to investigate the expression of EphB2 and EphB4 in breast carcinomas. Semiquantitative RT-PCR and immunohistochemistry were used to examine the expression patterns of EphB2 and EphB4. Clinicopathological and survival correlations were statistically analyzed in a series of 94 breast carcinomas, 9 normal specimens and 4 breast carcinoma cell lines. 1(1%), 16(17%), 29(31%), 48(51%) of the 94 tumors were negative, weak, moderate and strong EphB2 protein expression, respectively. 6(6%), 27(29%), 28(30%), 33(35%) of the tumors were negative, weak, moderate and strong EphB4 expression, respectively. Both EphB2 and EphB4 RTPCR products could be detected in all specimens. Increased EphB2 protein expression was negatively associated with overall survival, and there was a trend that increased EphB2 protein expression was correlated with shorter disease free survival, while EphB4 protein expression was associated with histological grade and stage. EphB4 membrane staining was increased with S phase fraction and associated with DNA aneuploidy. These findings indicate that both EphB2 and EphB4 are involved in the development of breast cancer and that both molecules could be potential predictive markers.
  •  
75.
  • Andersson, Håkan, 1944-, et al. (författare)
  • Comparison of the therapeutic efficacy of 211At- and 131I-labelled monoclonal antibody MOv18 in nude mice with intraperitoneal growth of human ovarian cancer.
  • 2001
  • Ingår i: Anticancer research. - 0250-7005. ; 21:1A, s. 409-12
  • Tidskriftsartikel (refereegranskat)abstract
    • The purpose of the present study was to compare the therapeutic efficacy of the alpha-emitter Astatine-211 with the beta-emitter Iodine-131 bound to the specific monoclonal antibody MOv18. The measurements were performed in an ovarian cancer cell line (NIH:OVCAR 3) growing intraperitoneally in nude mice. Two weeks after the intraperitoneal inoculation of 1 x 10(7) cells of the human ovarian cancer cell line NIH:OVCAR-3 twenty mice were treated intraperitoneally with the specific monoclonal antibody MOv-18 labelled with either 211At (310-400 kBq) or 131I (5100-6200 kBq). The pharmacokinetics and biodistribution of labelled antibody in tumour-free animals were studied and the resulting bone marrow dose was estimated. When the mice were treated with 211At-labelled antibody 9 out of 10 mice were free of macro- and microscopic tumour compared to 3 out of 10 when Iodine-131 was used. The equivalent dose to the bone marrow was 2.4-3.1 Sv from 211At- and 3.4-4.1 Sv from 131I-irradiation. The therapeutic efficacy of 211At-labelled specific antibody is very good and, at approximately equivalent bone marrow doses, better than that of 131I.
  •  
76.
  • Andersson, Håkan, 1944- (författare)
  • Radioimmunotherapy of experimental ovarian cancer with Astatine-211. An in vivo model for consolidation treatment in women
  • 2000
  • Doktorsavhandling (övrigt vetenskapligt)abstract
    • About 850 new cases of ovarian cancer are diagnosed in Sweden every year. In 75 % of the patients the tumour has spread outside the ovaries. The standard treatment is surgery followed by six courses of combination chemotherapy. In spite of a very high frequency of clinical complete responses the 5-year survival is not satisfactory. Thus there is a great need for consolidating therapy.Radioimmunotherapy (RIT), i.e. treatment with specific monoclonal antibodies (MAb) labelled with radionuclides has been tried for various tumours experimentally and clinically. In most studies b-emitters have been used but for micrometastases an a-emitter with a very short tissue range may be better.The purpose of this study was to examine the in vitro effect of the a-emitter Astatine-211 (211At) and to investigate the therapeutic efficacy of regional administration of the specific antibody MOv18 labelled with 211At to nude mice with intraperitoneal growth of human ovarian cancer. Methods. For the in vitro studies the two human cancer cell lines NIH:OVCAR-3 and Colo-205 were used. Cell suspensions were treated with free 211At, 211At-albumin, 211At-Mab or with photon irradiation. The human ovarian cancer cell line NIH:OVCAR-3 was used for the in vivo studies. Two weeks after the inoculation of cells, when the tumour still was microscopic, 211At-MOv18 was injected intraperitoneally. The therapeutic effect was evaluated six weeks later except in the long-term studyResults. In vitro the uptake of free 211At on both cell lines was unexpectedly high. A low number (19-31) of 211At decays on the cell surface was needed for 37% cell survival for both cell types.In the short term in vivo studies 18 of 20 mice were tumour-free when 211At-MOv18 was injected i.p. In the long-term study the survival was significantly better for treated than for untreated mice. Thirty-three per cent of the animals were tumour-free at the end of the study.Conclusion. Intraperitoneal radioimmunotherapy with an 211At-labelled specific antibody is an effective treatment of human ovarian cancer growing in nude mice. Hopefully, this treatment will be of value as consolidating treatment in women with minimal residual disease after surgery and chemotherapy
  •  
77.
  • Bernhardt, Peter, 1966-, et al. (författare)
  • Modelling of metastatic cure after radionuclide therapy: influence of tumor distribution, cross-irradiation, and variable activity concentration
  • 2004
  • Ingår i: Medical physics. - 0094-2405 (Print). ; 31:9, s. 2628-35
  • Tidskriftsartikel (refereegranskat)abstract
    • The objective was to study the influence of tumor number and size, cross-irradiation from normal tissue, and of variable activity concentration on metastatic cure after radionuclide therapy. A model to calculate the metastatic cure probability (MCP) was developed, in which it was assumed that the tumor response was an exponential function of the absorbed dose. All calculations were performed for monoenergetic electron emitters with different energies (10-1000 keV). The influence of tumor size and number of tumors were investigated with different log uniform distributions; the basic tumor distribution consisted of tumors with 1, 10, ..., 10(11) cells. The influence of cross-irradiation was assessed by calculating MCP for various tumor-to-normal tissue activity concentration ratios (TNC). The influence of variable activity concentration between tumors was calculated by assuming that the activity concentration in tumors was an inverse power law function of tumor mass. The required activity concentration (C0.9) and absorbed dose (D0.9) to obtain MCP=0.9 was calculated in the different models. The C0.9 and D0.9 needed to obtain MCP were very high; more than 25 MBq/g and 80 Gy, respectively. The lowest C0.9 and D0.9 for equal activity concentration in the different tumor sizes were obtained for electron energies less than 80 keV. For higher energies the low absorbed energy fraction in small tumors will increase the required C0.9 and D0.9 markedly. Cross-irradiation from normal cells surrounding the tumor will cause sterilization of the smallest tumors and decrease the required C0.9 and D0.9 for higher electron energies. Assuming that the activity concentration decreased with increased tumor mass caused a marked increase in C0.9 and D0.9 in favor of higher electron energies. With the MCP model we demonstrated significant influence of the number of tumors, their size, TNC and variable activity concentration on MCP. The results are valuable when evaluating optimal choices for radionuclides for internal-emitter therapy.
  •  
78.
  •  
79.
  •  
80.
  • Carlsson, Maria, 1958-, et al. (författare)
  • Treatment modality affects long-term quality of life in gynaecological cancer.
  • 2000
  • Ingår i: Anticancer Research. - The International Institute of Anticancer Research. - 0250-7005 .- 1791-7530. ; 20:1B, s. 563-568
  • Tidskriftsartikel (refereegranskat)abstract
    • In order to survey the side effects after cancer treatment, quality of life data were collected from females in clinical remission.MATERIALS AND METHODSThe study was cross-sectional; every patient that visited the outpatient clinic during a period of three months was asked to anonymously complete the EORTC QLQ-C30 questionnaire and five additional specific questions related to gynaecological cancer.RESULTSIn total, 235 patients (90%) returned the questionnaire. In general, both the levels of functioning and symptomatology were time-dependent. Patients with short treatment-free intervals reported more problems than the others. When using treatment modality as an independent variable in the statistical calculations, a treatment-related effect on functioning and symptomatology was demonstrated (p < 0.05 to p < 0.001). Patients previously treated with chemotherapy had poorer role- and cognitive functioning and more problems with fatigue, nausea, vomiting, dyspnoea, constipation and financial problems, compared with those not treated with chemotherapy (p < 0.05 to p < 0.01). Those patients who had been treated with external radiotherapy and/or brachytherapy had significantly more problems with flatulence and diarrhoea (p < 0.05 to p < 0.001). In conclusion, patients who underwent treatment for gynaecological cancer reported long-term side effects also many years after finishing treatment. The problems where related to treatment modality which should be considered, especially when planning adjuvant treatment.
  •  
Skapa referenser, mejla, bekava och länka
Åtkomst
fritt online (245)
Typ av publikation
tidskriftsartikel (866)
doktorsavhandling (74)
konferensbidrag (22)
forskningsöversikt (20)
bokkapitel (12)
annan publikation (1)
visa fler...
rapport (1)
visa färre...
Typ av innehåll
refereegranskat (870)
övrigt vetenskapligt (144)
populärvet., debatt m.m. (1)
Författare/redaktör
Olsson, Håkan, (50)
Borg, Åke, (43)
Li, Xinjun, (33)
Fernö, Mårten, (29)
Mertens, Fredrik, (29)
Möller, Torgil, (28)
visa fler...
Cavallin-Ståhl, Eva, (26)
Bendahl, Pär Ola, (23)
Glimelius, Bengt, (20)
Berglund, Göran, (20)
Hemminki, K (20)
Nilbert, Mef, (19)
Landberg, Göran (18)
Baldetorp, Bo, (18)
Larsson, Christer, (17)
Hemminki, Kari, (17)
Anderson, Harald (17)
Påhlman, Sven, (16)
Åkerman, Måns, (16)
Tennvall, Jan, (16)
Dasu, Alexandru (16)
Dillner, Joakim, (15)
Domanski, Henryk, (15)
Lennernäs, Bo, 1963- ... (14)
Blomqvist, Carl, (13)
Ahlman, Håkan, 1947- ... (13)
Strand, Sven-Erik, (13)
Hultborn, Ragnar, 19 ... (12)
Svanberg, Katarina, (12)
Wängberg, Bo, 1953-, (12)
Ringnér, Markus, (12)
Alvegård, Thor, (12)
Toma-Dasu, Iuliana, (12)
Axelson, Håkan, (12)
Stenram, Unne, (11)
Manjer, Jonas (11)
Mitelman, Felix, (11)
Nilsson, Ola, 1957-, (10)
Mattsson, Sören, (10)
Kjellén, Elisabeth (10)
Hallmans, Göran, (10)
Albertsson, Maria (10)
Härkönen, Pirkko, (10)
Gustafson, Pelle, (10)
Janzon, Lars, (10)
Willen, R. (10)
Dictor, Michael (10)
Wennerberg, Johan, (10)
Loman, Niklas, (10)
Jernström, Helena (10)
visa färre...
Lärosäte
Lunds universitet (707)
Karolinska Institutet (167)
Göteborgs universitet (135)
Uppsala universitet (101)
Umeå universitet (71)
Linköpings universitet (56)
visa fler...
Örebro universitet (27)
Stockholms universitet (9)
Södertörns högskola (6)
Ersta Sköndal Bräcke högskola (3)
Kungliga Tekniska Högskolan (2)
Högskolan i Jönköping (2)
Malmö universitet (2)
Högskolan i Halmstad (2)
Linnéuniversitetet (2)
Högskolan i Skövde (1)
Högskolan i Borås (1)
Högskolan i Gävle (1)
Blekinge Tekniska Högskola (1)
Röda Korsets Högskola (1)
visa färre...
Språk
Engelska (982)
Svenska (12)
Kinesiska (1)
Annat språk (1)
Forskningsämne (UKÄ/SCB)
Medicin och hälsovetenskap (996)
Naturvetenskap (13)
Samhällsvetenskap (3)
Teknik (2)
Humaniora (1)

År

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy